The impact of hepatitis C burden: an evidence-based approach
Article first published online: 26 JAN 2014
© 2014 John Wiley & Sons Ltd
Alimentary Pharmacology & Therapeutics
Volume 39, Issue 5, pages 518–531, March 2014
How to Cite
Younossi, Z. M., Kanwal, F., Saab, S., Brown, K. A., El-Serag, H. B., Kim, W. R., Ahmed, A., Kugelmas, M. and Gordon, S. C. (2014), The impact of hepatitis C burden: an evidence-based approach. Alimentary Pharmacology & Therapeutics, 39: 518–531. doi: 10.1111/apt.12625
- Issue published online: 4 FEB 2014
- Article first published online: 26 JAN 2014
- Manuscript Accepted: 30 DEC 2013
- Manuscript Revised: 29 DEC 2013
- Manuscript Revised: 11 OCT 2013
- Manuscript Received: 2 OCT 2013
- Gilead Sciences
Infection with the hepatitis C virus (HCV) has been considered a major cause of mortality, morbidity and resource utilisation in the US. In addition, HCV is the main cause of hepatocellular cancer (HCC) in the US. Recent developments in the diagnosis and treatment of HCV, including new recommendations pertaining to screening for HCV by the Centers for Disease Control and Prevention and newer treatment regimens with high efficacy, short duration and the potential for interferon-free therapies, have energised the health care practitioners regarding HCV management.
To assess the full impact of HCV burden on clinical, economic and patient-reported outcomes.
An expert panel was convened to assess the full impact of HCV burden on a number of important outcomes using an evidence-based approach predicated on Grading of Recommendations Assessment, Development and Evaluation methodology. The literature was summarised, graded using an evidence-based approach and presented during the workshop. Workshop presentations were intended to review recent, relevant evidence-based literature and provide graded summary statements pertaining to HCV burden on topics including the relationships between HCV and the development of important outcomes.
The associations of HCV with cirrhosis, HCC, liver-related mortality, type 2 diabetes mellitus, rheumatological diseases and quality of life impairments are supported by strong evidence. Also, there is strong evidence that sustained viral eradication of HCV can improve important outcomes such as mortality and quality of life.
The current evidence suggests that HCV has been associated with tremendous clinical, economic and quality of life burden.